Catalog No.
Product Name
Application
Product Information
Citations
-
Drug Impurity
Betamethasone dipropionate impurity 7 is identified as an impurity associated with Betamethasone dipropionate. Its characterization is essential for ensuring the purity and quality of pharmaceutical formulations containing Betamethasone dipropionate. This compound serves as a reference standard for analytical techniques such as HPLC and mass spectrometry, facilitating method development and validation in quality control laboratories. -
Drug Impurity
Afatinib impurity 31 is a defined impurity related to the tyrosine kinase inhibitor Afatinib, which primarily targets EGFR (epidermal growth factor receptor). This compound serves as a reference standard for quality control in the synthesis and formulation of Afatinib, facilitating the assessment of drug purity in research and development settings. Its characterization is essential for ensuring compliance with regulatory standards in pharmaceutical applications. -
Drug Impurity
Azilsartan impurity 19, also known as N-Ethyl azilsartan medoxomil, is a drug impurity associated with Azilsartan. This compound serves as a reference standard for analytical chemistry applications, particularly in the quality control and validation of Azilsartan formulations. Its presence and characterization are essential for ensuring the safety and efficacy of pharmaceutical products containing Azilsartan. -
Drug Impurity
Ethambutol impurity 2 is a known impurity associated with the antitubercular agent Ethambutol. This compound serves as a critical reference standard in the quality control of Ethambutol formulations, aiding in the assessment of drug purity and the identification of potential contaminants. Its presence can significantly influence pharmacokinetic and therapeutic profiles, making it valuable for analytical studies and regulatory compliance in pharmaceutical research. -
Drug Impurity
Bumetanide impurity 2 is a recognized impurity associated with the diuretic agent Bumetanide. This compound serves as a critical reference standard for the assessment of purity in pharmaceutical formulations. Its analysis is essential for ensuring the safety and efficacy of drug products containing Bumetanide. Researchers can utilize this impurity in method development and validation studies within quality control laboratories. -
Drug Impurity
Diclofenac impurity 2 is a drug impurity associated with the pharmaceutical compound Diclofenac. It is primarily utilized in the pharmaceutical research and development sectors to ensure the safety and efficacy of drug formulations. The identification and quantification of this impurity are critical for compliance with regulatory standards and for understanding the drug's overall pharmacological profile. -
Drug Impurity
Clopidogrel impurity 7 bromide is a recognized impurity associated with Clopidogrel bromide, serving as an important component in drug quality control. This compound is utilized in analytical chemistry and pharmaceutical development to assess the purity and stability of clopidogrel formulations. Its identification and characterization are crucial for ensuring compliance with regulatory standards in drug manufacturing. -
Impurity of Valsartan
D-Valsartan is an impurity of Valsartan, which functions primarily as an angiotensin II receptor antagonist. It plays a critical role in the characterization of Valsartan and is essential for purity assessments during pharmaceutical development. This compound serves as a reference in research applications aimed at understanding the pharmacological profile and safety of angiotensin II receptor modulators. -
Process-related Impurity
NW-1689 is a process-related impurity of safinamide mesilate (SAFM) and exhibits similar chemical characteristics. It functions primarily as a reversible inhibitor of monoamine oxidase-B (MAO-B) and shares pharmacological properties with SAFM, contributing to reduced dopamine degradation and glutamate release. This compound is relevant for research focused on Parkinson's disease, supporting investigations into neuroprotective mechanisms and potential therapeutic effects. -
Heroin Impurity
ATM4 4-Acetoxy analog is identified as an impurity associated with the synthesis of heroin. This compound plays a notable role in chemical research related to opioid synthesis and quality control. Its characterization is crucial for understanding the intricacies of heroin production and ensuring regulatory compliance within drug development processes. -
Amphetamines Impurity
1,2-Dibromo-4,5-methylenedioxybenzene is an impurity associated with the synthesis of amphetamines. This compound is relevant for analytical research and quality control in the production of amphetamine derivatives. Its presence may influence the pharmacological properties of synthesized compounds, making it an important target for study in chemical research focused on amphetamine-related substances. -
Drug Impurity
(1S,2R)-2-Fluorocyclopropan-1-amine hydrochloride is a chemical compound often encountered as a drug impurity. Its primary target is related to its role in the synthesis and analysis of various pharmaceutical formulations. This reagent is utilized in research applications focused on evaluating drug purity, stability, and potential biological impacts of impurities in pharmacological studies. -
Drug Impurity
Naproxen Impurity 4 is a characterized impurity associated with the nonsteroidal anti-inflammatory drug (NSAID) Naproxen. This compound is significant for quality control and analytical assessments in pharmaceutical research, providing insights into the purity and stability of Naproxen formulations. Its analysis can aid in understanding the compound's safety profile and potential effects on efficacy during drug development. -
Drug Impurity
Propofol Impurity 1 is a known impurity of the anesthetic agent Propofol, primarily used in the study of drug formulation purity and stability. Its characterization is essential for ensuring the quality of Propofol in pharmaceutical applications. Research involving this impurity can provide insights into the metabolization and potential effects associated with Propofol administration, contributing to safer therapeutic practices. -
Drug Impurity
3,5-Dimethylbenzonitrile serves as a drug impurity often encountered during synthetic processes. This compound is important for quality control in pharmaceutical research, aiding in the identification and quantification of unintended byproducts. Its presence is relevant in the assessment of drug safety and efficacy, making it a valuable reagent in analytical chemistry and toxicology studies. -
Drug Impurity
Rivaroxaban impurity 43 is a specific impurity associated with the anticoagulant Rivaroxaban. This chemical reagent is primarily utilized in the characterization and analysis of Rivaroxaban formulations to ensure quality control and compliance with pharmaceutical standards. Its presence can impact the pharmacokinetics and safety profile of the drug, making it an essential component in drug formulation research and development. -
Drug Impurity
Olmesartan impurity 13 is a specific impurity associated with the angiotensin II receptor blocker, Olmesartan. This compound is important for analytical and quality control applications in pharmaceutical research, particularly in ensuring the purity and safety of Olmesartan formulations. Its presence can impact the efficacy and safety profile of the drug, making it a relevant focus in pharmacological studies and drug development processes. -
Drug Impurity
Amodiaquine impurity 1 is a drug impurity associated with Amodiaquine, a chloroquine derivative primarily utilized in antimalarial therapy. This impurity may impact the pharmacodynamics and stability of the parent compound, making it crucial for analytical and quality control studies in pharmaceutical research. Its characterization is essential for understanding drug formulation and ensuring compliance with regulatory standards. -
Drug Impurity
Nintedanib Impurity 6 is a drug impurity associated with the pharmaceutical compound Nintedanib, which acts as a multi-tyrosine kinase inhibitor. Its primary mechanism involves inhibiting kinases such as VEGFR, PDGFR, and FGFR, which are implicated in angiogenesis and tumor growth. This impurity may be used for analytical purposes in the development and quality control of Nintedanib, ensuring the integrity and safety of pharmaceutical formulations. Research applications include purity assessment and stability studies within pharmaceutical chemistry. -
Drug Impurity
Theophylline impurity 9 is a known impurity identified in Theophylline. This compound serves as an important reference standard in the analysis and quality control of pharmaceutical formulations. Its characterization is crucial for ensuring compliance with regulatory standards and for understanding the pharmacological profile of Theophylline-containing products in therapeutic and research contexts. -
Drug Impurity
Indobufen impurity 4 is a minor impurity derived from Indobufen, a known antiplatelet agent. This compound is relevant for analytical research in pharmacokinetics and quality control, allowing for comprehensive impurity profiling in drug formulations. Its characterization is essential for ensuring the safety and efficacy of therapeutic agents in development. -
Drug Impurity
N-Methyl-3-nitroaniline is a nitroaniline derivative primarily recognized for its role as a drug impurity. This compound is significant in chemical research for assessing purity levels and evaluating potential safety profiles of pharmaceutical formulations. N-Methyl-3-nitroaniline serves as a critical marker in stability studies and quality control processes within the drug development pipeline. -
Drug Impurity
Levetiracetam impurity 1 is a known impurity associated with the anticonvulsant agent Levetiracetam, primarily targeting the modulation of neurotransmitter release. This impurity can serve as a reference standard in analytical chemistry and pharmacokinetics studies, aiding in the evaluation of drug purity and stability. It is particularly useful in the development and quality control of pharmaceutical formulations containing Levetiracetam. -
Drug Impurity
Noradrenalone impurity 1 hydrochloride is a chemical compound characterized as an impurity of Noradrenalone. It serves as a reference standard for quality control in drug formulation and development, enabling researchers to investigate potential impurities in pharmaceutical products. This reagent is essential for ensuring the purity and safety of Noradrenalone in various biological and chemical research applications. -
Drug Impurity
Umeclidinium bromide impurity 8 is a known impurity of Umeclidinium bromide, which acts as a long-acting muscarinic antagonist (LAMA). This compound is primarily utilized for analytical purposes, especially in the characterization and quality control of pharmaceutical formulations containing Umeclidinium bromide. Its presence and quantification are crucial for ensuring compliance with regulatory standards in drug development and manufacturing. -
Drug Impurity
Clozapine impurity 8 is a known impurity of the atypical antipsychotic clozapine, primarily identified for its role in therapeutic formulations. This compound is essential for assessing the quality and safety of clozapine, aiding in the understanding of its metabolic profile and overall pharmacological impact. Researchers can utilize this impurity in drug development and analytical studies to ensure compliance with regulatory standards for pharmaceutical products. -
Drug Impurity
Tofacitinib impurity 6 is a chemical impurity associated with Tofacitinib, a selective Janus kinase (JAK) inhibitor. It is primarily used to support analytical evaluations and quality control in pharmaceutical research involving Tofacitinib. This compound is essential for the identification and quantification of impurities, facilitating the maintenance of drug safety and efficacy standards. -
Drug Impurity
Sildenafil Impurity 1 is a known impurity of the phosphodiesterase type 5 inhibitor, Sildenafil. Characterized for its relevance in pharmacological studies, this compound serves as a critical reference standard for quality control in the synthesis and analysis of Sildenafil. Its identification and quantification are essential in ensuring the purity and safety of pharmaceutical formulations containing Sildenafil. -
Drug Impurity
Paliperidone impurity 15 is a chemical impurity associated with the antipsychotic agent paliperidone. This impurity serves as a key component for studies focused on the characterization and analysis of pharmaceutical formulations. It is essential for quality control and regulatory compliance in the production of paliperidone and may be utilized in analytical research to elucidate the compound's purity profile. -
Drug Impurity
Candesartan impurity 26 is a known impurity of the angiotensin II receptor blocker, Candesartan. Its presence is significant in the analysis of pharmaceutical formulations and quality control processes. This compound is essential for researchers conducting stability studies, impurity profiling, and regulatory compliance in drug development. -
Drug Impurity
Ethinylestradiol impurity 3 is a known impurity associated with the synthesis of Ethinylestradiol, a synthetic estrogen used in various hormonal therapies. This compound can be utilized in quality control and analytical studies to evaluate the purity of Ethinylestradiol formulations. Its presence in pharmaceutical preparations can affect the efficacy and safety profiles of estrogenic treatments, making it relevant in drug development and regulatory assessments. -
Drug Impurity
Apixaban impurity 46 is a characterized impurity associated with the anticoagulant Apixaban. This compound is crucial for the quality control and validation processes in pharmaceutical research, aiding in the assessment of drug purity and stability. Its analysis is essential for ensuring compliance with regulatory standards in drug development and manufacturing, ultimately contributing to safer therapeutic applications. -
Drug Impurity
Ondansetron impurity 6 is a known impurity associated with the antinausea medication Ondansetron. This compound is essential for assessing the purity and quality of pharmaceutical formulations containing Ondansetron. It serves a critical role in research focused on drug development, formulation stability, and regulatory compliance by providing insights into the compound's synthesis and degradation pathways. -
Drug Impurity
Methyl 2-formyl-5-methoxybenzoate is identified as a drug impurity. This compound may participate in various analytical studies aimed at assessing the purity of pharmaceutical formulations. It is useful for researchers investigating the stability and degradation pathways of benzoate derivatives within the context of drug development. -
Drug Impurity
Methyl 5-formylsalicylate is a recognized drug impurity associated with various pharmaceutical compounds. This compound can serve as an important analytical marker for quality control and stability testing throughout drug development processes. Its examination can provide insights into the metabolic pathways and degradation products of certain drug formulations, aiding in the evaluation of safety and efficacy. -
Drug Impurity
Nintedanib impurity 9 is a specific impurity associated with the drug Nintedanib, which serves as a multiple receptor kinase inhibitor targeting VEGFR, PDGFR, and FGFR. This compound is utilized in research to assess the purity and quality of Nintedanib formulations. Its identification is crucial for compliance with regulatory standards in drug development and quality control processes. -
Drug Impurity
Glycopyrronium impurity 4 is a chemical impurity associated with the synthesis of Glycopyrronium, a muscarinic receptor antagonist. This impurity is relevant for quality control and regulatory compliance during the development and manufacture of pharmaceutical formulations. It can be utilized in analytical studies to assess the purity and stability of Glycopyrronium formulations. -
Drug Impurity
Cinakase impurity 11 is a byproduct associated with the synthesis of Cinakase, a medication used for the treatment of certain hematological malignancies. This impurity is essential for analytical validation and quality control in pharmaceutical research. Its characterization aids in ensuring the safety and efficacy of the final therapeutic product, facilitating compliance with regulatory standards in drug development. -
Drug Impurity
Sitagliptin impurity 5 is a structural variant of Sitagliptin, primarily characterized as a drug impurity. It is utilized in pharmaceutical research and development to understand the profiles and effects of Sitagliptin formulations. This impurity plays a crucial role in chromatographic analysis and quality control assessments of Sitagliptin products, ensuring the integrity and safety of therapeutic compounds. -
Drug Impurity
Prednisolone Impurity 9 is a chemical impurity associated with the corticosteroid prednisolone. Characterizing this impurity is essential for ensuring the quality and safety of pharmaceutical formulations. This reagent is utilized in analytical and quality control studies to identify and quantify impurities, contributing to the overall understanding of drug stability and efficacy. -
Drug Impurity
Furosemide Impurity 7 is a chemical impurity associated with the pharmaceutical compound Furosemide. As a drug impurity, it is relevant for studies focusing on pharmaceutical quality control and toxicological assessments. Research applications include the evaluation of drug purity and stability, as well as understanding the implications of impurities in drug formulations. -
Drug Impurity
Ticagrelor impurity 20 is a chemical impurity associated with the antiplatelet agent Ticagrelor. This compound serves as an important reference standard in the evaluation of Ticagrelor quality and purity. It is utilized in pharmaceutical research and development to ensure the integrity of formulations containing Ticagrelor and to study the effects of impurities on drug efficacy and safety. -
Drug Impurity
Peracetyl Empagliflozin is a known drug impurity related to the SGLT2 inhibitor Empagliflozin. This compound may be utilized in the study of pharmaceutical formulations and stability testing, helping to assess the quality and safety of drug products. Its characterization can provide valuable insights into synthesis pathways and potential degradation mechanisms, supporting research in drug development and regulatory compliance. -
Drug Impurity
Avibactam impurity 1 is a chemical impurity associated with Avibactam, a β-lactamase inhibitor. This compound is critical for quality control and characterization in pharmaceutical research and development. Its analysis is essential for ensuring the purity of Avibactam in clinical formulations and contributes to investigations on drug stability and efficacy. -
Drug Impurity
Dapagliflozin impurity 57 is a chemical impurity associated with Dapagliflozin, an SGLT2 inhibitor used in the treatment of type 2 diabetes. This compound serves as a key reference standard for analytical characterization and quality control in pharmaceutical research. Its presence is crucial for ensuring the purity and safety of therapeutic formulations containing Dapagliflozin, making it essential for regulatory compliance and stability testing. -
Drug Impurity
Ropivacaine impurity 1 hydrochloride is a known impurity related to the local anesthetic Ropivacaine. This compound serves as an important reference standard for the assessment of drug quality and purity in pharmaceutical research and development. Its characterization is crucial for regulatory compliance and ensuring the safety and efficacy of Ropivacaine formulations. -
Drug Impurity
Methotrexate impurity 6 is a known impurity associated with the chemotherapeutic agent Methotrexate. This compound is primarily used for analytical purposes in pharmacokinetic studies and quality control processes. It serves as a reference standard for identifying and quantifying impurities in pharmaceutical formulations containing Methotrexate. -
Drug Impurity
Ticagrelor impurity 25 is a synthetic impurity associated with the antiplatelet agent Ticagrelor, acting primarily on the P2Y12 receptor to inhibit platelet aggregation. This compound serves as a crucial reference material in the analysis and quality control of Ticagrelor formulations, ensuring the purity and efficacy of the drug. Its characterization is essential for pharmacokinetic studies and the development of regulatory guidelines in pharmaceutical research. -
Drug Impurity
Trimetazidine impurity 10 is a chemical impurity associated with the cardioprotective agent Trimetazidine. As a research reagent, it can be utilized in the analysis of Trimetazidine's purity and stability, helping to ensure compliance with pharmacological standards. This impurity is significant for studies involving drug formulation and quality control in pharmaceutical research. -
Drug Impurity
Sorafenib impurity 6 is a known impurity of the multikinase inhibitor Sorafenib, targeting various receptor tyrosine kinases involved in tumor angiogenesis and cell proliferation. This compound serves as a useful reference standard in analytical chemistry and pharmacokinetic studies to assess the purity of Sorafenib formulations. Its characterization aids in ensuring the quality and efficacy of pharmaceutical products containing Sorafenib.
